ON-DEMAND WEBINAR Defining Specificity within the ELISpot Assay
February 23, 2022 11 am EST
On-Demand AVAILABLE "Defining Specificity within the ELISpot Assay" Presented by TJ Beadnell, PhD, Scientific Manager, R&D.
Eurofins BioPharma Newsletter- February 2022
Check out the latest BioPharma Newsletter
World Vaccine Congress- Washington DC
April 18-21 2022
Join Eurofins Viracor BioPharma at the upcoming World Vaccine Congress in Washington DC. Thomas Beadnell will be presenting on April 20th at 2:40 EST on "Specificity and Utility of ELISpot in Vaccine Clinical Development".
DDR, ATR & PARP Inhibitors
January 25-27, 2022
Eurofins Viracor BioPharma will be attending at the DDR 5th Annual PARP, ATR & DDR Inhibitors Summit which is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications.
ON DEMAND: Viral shedding and infectivity testing in clinical trials of Oncolytic virotherapy
VIEW ON DEMAND "Viral shedding and infectivity testing in clinical trials of Oncolytic virotherapy" presented by Kristen Mickey, Research Scientist, R&D.
Eurofins BioPharma Newsletter- October 2021
Check out the latest BioPharma Newsletter featuring how Eurofins Viracor targets precision oncology with the launch of PanCancer IQ™ and learn about new services and analytical techniques, research projects and other related topics.
15th WRIB 27 Sept- 1 Oct 2021
27 Sep- 1 Oct 2021
Eurofins will be attending the 15th WRIB and excited to share how our specialized expertise in complex bioassay design, optimization, validation and transfer, customized to your study’s needs — together with testing performed in our high throughput CAP/CLIA laboratory can advance your study design and clinical trial program.
World Vaccine and Immunotherapy Congress 2021
30 Nov- 2 Dec 2021
Eurofins Viracor BioPharma will be exhibiting and sponsoring the World Vaccine and Immunotherapy Congress and we are excited to share our specialized expertise in complex bioassay design, optimization, validation and transfer, customized to your study’s needs.
6th Annual Oncolytic Virotherapy Summit
26-28 Oct 2021
Eurofins Viracor BioPharma will be exhibiting and sponsoring the 6th Annual Oncolytic Virotherapy Summit in Boston, October 26-28th, and we are excited to share our latest comprehensive assay offering for next generation sequencing to enable genomic profiling of tumor samples with PanCancerIQ™. Kristen Mickey will be presenting on October 28th "Viral shedding and infectivity testing in clinical trials of oncolytic virotherapies".
Eurofins Viracor BioPharma Immunotherapy Force Multiplier
It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.
Connect With Our Experts